Global pharma major Dr. Reddy’s Laboratories has got approval from United States Food and Drug Administration (USFDA) for Azacitidine Injection 100 mg/vial on September 16.

Generic drug

Azacitidine is a bioequivalent generic version of VIDAZA{+®}(azacitidine for injection). The company is planning the launch of the product in the market in near-term.

Considering the annual sales of generic version, Azacitidine is expected to be the drug of high potential in terms of revenue. The annual sales of VIDAZA{+®}brand registered around $378.5 in twelve months ending July 2013 according to IMS Health.

Dr. Reddy’s Azacitidine for injection 100 mg/vial is available in single use-vials.